Date: 2015-12-08
Type of information: Research agreement
Compound: Anticalin®-based drug candidates against an undisclosed target
Company: Pieris (Germany) Roche (Switzerland)
Therapeutic area: Cancer - Oncology
Type agreement: research - R&D - licensing
Action mechanism:
- protein. Anticalins® are engineered human proteins that are able to bind specific target molecules. Pieris is developing bispecific Anticalin-based protein therapeutics against a variety of tumor and immunomodulatory targets. These compounds aim to activate the immune system in the tumor microenvironment, with the goal of increasing efficacy as well as improving safety compared to existing approaches.
Disease:
Details:
- • On December 8, 2015, Pieris Pharmaceuticals announced a research collaboration and license agreement with Roche in cancer immunotherapy (CIT). Under the terms of the agreement, Pieris will discover, characterize and optimize Anticalin®-based drug candidates against an undisclosed target. Roche and Pieris will evaluate different drug formats against this target and advance them through preclinical development, with Roche being responsible for IND-enabling activities, clinical development and worldwide marketing of any resulting products.
- This collaboration represents Pieris' first partnered immuno-oncology program and leverages Pieris' capability to address a target in multiple ways through Anticalin-based drug candidates in different formats.
Financial terms:
- Pieris will receive an upfront payment of CHF 6.5 million (~$6.4 million USD) and committed research funding, and may receive development and regulatory-based milestone payments, sales-based milestone payments as well as mid single-digit to low double-digit royalties on any future product sales.
- If all milestones and other conditions are met, the total payments to Pieris could surpass CHF 415 million (~$409.3 million USD), excluding royalties.
Latest news:
Is general: Yes
